Schedule II & RFK ·
State-level peptide legislation has proliferated in 2026, partly in response to federal policy discussions and partly reflecting distinct state priorities. Several states have introduced or passed bills addressing state-level scheduling of peptide-category substances, state pharmacy board oversight of peptide compounding, and state-specific licensing requirements for telehealth providers prescribing peptides. Texas, Florida, Arizona, and Utah have been particularly active. The resulting patchwork of state rules means that the legal status of a given peptide can vary significantly across state lines, complicating compliance for multistate operators and influencing consumer behavior.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.